Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
NCT06620809Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Mar 2025
- Primary completion
- Nov 2027
- Modality
- Lipid-based Nanoparticles, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NouvSoma001 in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Incidence and severity of all adverse events and serious adverse events at 6 months. Started Mar 2025; status: recruiting.
02
Drugs
NouvSoma001
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT06620809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620809.